EDGEWISE THERAPEUTICS INC (EWTX)

Company Profile

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Boulder, Colorado and currently employs 108 full-time employees. The company went IPO on 2021-03-26. The company is focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company has built its muscle-focused drug discovery platform. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. Its lead product candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. Its product candidate, EDG-7500, for the treatment of hypertrophic cardiomyopathy addition to exploring the potential of its mechanism in the treatment of disorders of diastolic dysfunction.

Company Info

EDGEWISE THERAPEUTICS INC

1715 38Th St

Boulder COLORADO 80303

P: 17202627002

CEO: Kevin Koch

Employees: 97

Website: https://edgewisetx.com/